Skip to main content
Clinical Trials/JPRN-UMIN000014486
JPRN-UMIN000014486Completed未知

Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritis - Saitama East Study

Saitama East Study Group0 sites100 target enrollmentStarted: December 1, 2014Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1.Patients have other rheumatic diseases. 2. Patients have malignant disorders in recent 5 years. 3.Patients have a risk for tuberculosis. 4.Patients who develpoprd bacterial infection and antibiotics were administrated within 30 days after first CPZ treatment. 5.Drug or alcohol addiction or abusers. 6.Patients who are not able to be adequately evaluated in this study. 7.Patients who have Type B viral hepatitis. 8.Patients who have nontuberculous mycobacteril infection. 9.Patients who have congestive heart failure(>II).

Investigators

Sponsor
Saitama East Study Group

Similar Trials